{
    "clinical_study": {
        "@rank": "136038", 
        "arm_group": [
            {
                "arm_group_label": "Radiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiotherapy  2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer"
            }, 
            {
                "arm_group_label": "Raltitrexed/Oxaliplatin  Plus Radiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Raltitrexed 2.5mg/\u33a1 d1,Oxaliplatin 100mg/\u33a1 d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable  esophageal cancer"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study was to compare  raltitrexed/oxaliplatin plus radiotherapy versus\n      radiotherapy in subjects with inoperable esophageal cancer."
        }, 
        "brief_title": "A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Inoperable Esophageal Cancer Stage I-III", 
        "condition_browse": {
            "mesh_term": "Esophageal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "108 patients were randomized to receive Raltitrexed/Oxaliplatin Plus Radiotherapy\n      (Raltitrexed 2.5mg/\u33a1 d1,Oxaliplatin 100mg/\u33a1 d1,q21d Plus Radiotherapy 2.0Gy/day, 5\n      times/week,6 weeks.)or Radiotherapy ( Radiotherapy 2.0Gy/day, 5 times/week,6 weeks) in\n      subjects with Inoperable esophageal cancer. All patients will receive therapy of six weeks\n      unless disease progression or unacceptable toxicity. Patients were evaluated every 3 months\n      .Progression-Free-Survival was the primary endpoint. Response Rate, Overall survival,\n      toxicity of the therapy are other second endpoint."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of inoperable esophageal cancer(squamous cell carcinoma)\n\n          -  Measurable disease according to RECIST criteria\n\n          -  Age > 18 years\n\n          -  WHO performance score < 2\n\n          -  Estimated life expectancy of > 12 weeks\n\n          -  Subjects will be considered appropriate to receive systemic chemotherapy and pelvic\n             radiotherapy\n\n          -  Hematologic function: WBC \u2265 4.0\u00d7109/L, PLT \u2265 80\u00d7109/L, Hb \u2265 10mg/dL\n\n          -  Renal function: Cr \u2264 1.25\u00d7UNL\n\n          -  Hepatic function: BIL \u2264 1.5\u00d7UNL, ALT/AST \u2264 2.5\u00d7UNL\n\n          -  Documented informed consent to participate in the trial\n\n        Exclusion Criteria:\n\n          -  Subjects with distant metastases\n\n          -  Pregnancy or breast feeding. Women of childbearing age must use effective\n             contraception\n\n          -  Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,\n             unstable angina, myocardial infarction, serious heart valve disease, resistant\n             hypertension)\n\n          -  Evidence of bleeding diathesis or serious infection\n\n          -  pregnant or lactating woman\n\n          -  Patient participation in other studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732380", 
            "org_study_id": "1stPeopleLianyungang"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltitrexed/Oxaliplatin  Plus Radiotherapy", 
                "intervention_name": "Raltitrexed", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TOMUDEX", 
                    "Sai Wei Jian"
                ]
            }, 
            {
                "arm_group_label": "Raltitrexed/Oxaliplatin  Plus Radiotherapy", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Eloxatin"
            }, 
            {
                "arm_group_label": [
                    "Radiotherapy", 
                    "Raltitrexed/Oxaliplatin  Plus Radiotherapy"
                ], 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Raltitrexed"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 19, 2012", 
        "location": {
            "contact": {
                "email": "jxdysy1970@163.com", 
                "last_name": "Xiaodong Jiang, Doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Lianyungang", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "222002"
                }, 
                "name": "The First People`s Hospital of Lianyungang"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomized Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer", 
        "other_outcome": {
            "description": "People in a study or treatment group who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease, such as cancer. The overall survival is often stated as a five-year survival, which means  people in a study or treatment group who are alive five years after their diagnosis or the start of treatment.", 
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "overall_contact": {
            "email": "jxdysy1970@163.com", 
            "last_name": "Xiaodong Jiang, Doctor", 
            "phone": "86-0518-85469074"
        }, 
        "overall_official": {
            "affiliation": "The First People`s Hospital of Lianyungang", 
            "last_name": "Xiaodong Jiang, Doctor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival (PFS) is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse.", 
            "measure": "Progression-Free-Survival", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "reference": [
            {
                "PMID": "20645400", 
                "citation": "Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010 Oct;97(10):1482-96. Review."
            }, 
            {
                "PMID": "17329193", 
                "citation": "Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar;8(3):226-34."
            }, 
            {
                "PMID": "20839062", 
                "citation": "McKenzie S, Mailey B, Artinyan A, Metchikian M, Shibata S, Kernstine K, Kim J. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy. Ann Surg Oncol. 2011 Feb;18(2):551-8. Epub 2010 Sep 14."
            }, 
            {
                "PMID": "12176786", 
                "citation": "Seitz JF, Bennouna J, Paillot B, Gamelin E, Fran\u00e7ois E, Conroy T, Raoul JL, Becouarn Y, Bertheault-Cvitkovic F, Ychou M, Nasca S, Fandi A, Barthelemy P, Douillard JY. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol. 2002 Jul;13(7):1072-9."
            }, 
            {
                "PMID": "12075739", 
                "citation": "Cascinu S, Graziano F, Ferra\u00f9 F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol. 2002 May;13(5):716-20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Response rate (RR) is a figure representing the percentage of patients whose cancer shrinks (termed a partial response, PR) or disappears after treatment (termed a complete response, CR) . In simpler terms RR=PR+CR.", 
            "measure": "Response Rate", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "source": "The First People's Hospital of Lianyungang", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The East Hospital of Lianyungang", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The People's Hospital of  Donghai", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The People's Hospital of  Ganyu", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "The First People's Hospital of Lianyungang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}